Results 201 to 210 of about 64,826 (258)

Joint Disease and Demographic Factors in Clinical Populations of Medically Underserved Communities. [PDF]

Orthop Rev (Pavia)
Martin BC, Lopez-Alvarenga J, Sander MD.
europepmc   +1 more source

Exploring Risks of Adverse Drug Events From Single Drug to Three‐Drug Combination

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Use of three‐drug combinations is common and could increase the risk of adverse drug events (ADEs). Signals of ADEs from three‐drug combinations could be identified from real‐world data, and the risks of ADEs from single drug exposure to three‐drug combination exposure could be illustrated by a graphic model.
Yi Shi, Anna Sun, Chien‐Wei Chiang, Yuedi Yang, Katherine M. Hunold, Jing Xu, Mu Shan, Allison Lu, Massimiliano Russo, Jeffrey M. Caterino, Michael T. Eadon, Lang Li, Jing Su, Macarius Donneyong, Pengyue Zhang   +14 more
wiley   +1 more source

The association between the triglyceride-glucose index and serum uric acid: a systematic review and meta-analysis. [PDF]

BMC Endocr Disord
Feng L, Fan H, Rao X, Tang T, Shi Y, Yu Q, Tong X, Fu X, Xu Z, Chen J, Zhang X, Wang H, Tang J, Wang M.   +13 more
europepmc   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

Tophaceous gout

Journal of Hospital Medicine
Tyler B. Larsen, Michael E. Lazarus
openaire   +3 more sources

Uric Acid and Chronic Kidney Disease. [PDF]

Kidney Med
Yadlapalli S, Nekkalapudi DK, Wish JB.
europepmc   +1 more source

Clinicopathological findings, correlations and outcomes in patients with renal disease and living with antiretroviral‐treated human immunodeficiency virus infection

Internal Medicine Journal, Volume 56, Issue 8, Page 1402-1411, August 2026.
Abstract Background and Aims Antiretroviral therapy (ART) has modified the incidence of renal complications and the patterns of renal disease in people living with Human Immunodeficiency Virus (PLWH). We reviewed (2011–2021) the progress and outcomes (follow‐up to mid‐2025) of 158 such individuals.
Jacqueline A. Evans, Christopher S. B. Sia, Gopal Basu, Orla O’Brien, Alan H. Pham, Rowan G. Walker   +5 more
wiley   +1 more source

Shift work, genetic risk, and incident gout: a prospective cohort study in the UK Biobank. [PDF]

Arch Public Health
Wu C, Zhang H, Xia J, Peng B, Chen J, Wang M, Wu S, Jiang Z, Ji S, Yang Y, You Y, Kwan HY, Sun Z, Zhao X, Liu Y.   +14 more
europepmc   +1 more source

Gout furonculosis

Joint Bone Spine, 2019
openaire   +4 more sources

[Gout of the manubriosternal joints: A case report]. [PDF]

Beijing Da Xue Xue Bao Yi Xue Ban
Gan D, Fu Q, Tang X, Li C, Shu Z.
europepmc   +1 more source